Treatment adherence

South African Journal of Psychiatry

Volumn 13, Issue 2, 2007, Pages 40-45

  Moosa, M Y H ^a   Jeenah, F Y ^a   Kazadi, N ^a  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

AGE DISTRIBUTION; ARTICLE; CAREGIVER BURDEN; CLINICAL TRIAL; COST CONTROL; DOCTOR PATIENT RELATION; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; HEALTH CARE COST; HEALTH CARE DELIVERY; HEALTH CARE NEED; HEALTH CARE QUALITY; HEALTH CARE SYSTEM; HUMAN; MENTAL DISEASE; MENTAL HEALTH CARE; PATIENT ATTITUDE; PATIENT COMPLIANCE; PATIENT EDUCATION; PATIENT PARTICIPATION; PUBLIC HEALTH; SCHIZOPHRENIA; SELF REPORT; SEX DIFFERENCE; SOCIAL STATUS; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT REFUSAL; UNSPECIFIED SIDE EFFECT;

EID: 36148929048     PISSN: 16089685     EISSN: None     Source Type: Journal    
DOI: 10.4102/sajpsychiatry.v13i2.26     Document Type: Article

References (60)

1. DiMatteo MR, DiNicola DD. Achieving Patient Compliance. The Psychology of the Medical Practitioner's Role. Elmsford NJ: Pergamon Press, 1982; 1-28.
2. Perkins DO. Predictors of noncompliance in patients with schizophrenia. J Clin Psychiatry 2002; 63: 12-16.
3. Cramer JA, Rosenbeck R. Compliance with medication regimens for mental and physical disorders. Psychiatr Serv 1998; 49: 196-201
4. Venturini F. Utilisation patterns of anti-depressant medications in a patient population served by a primary care medical group. Journal of Managed Care Pharmacy 1999; 5: 243-249.
5. Lin EH. The role of the primary care physician in patient's adherence to anti depressant therapy. Med Care 1995; 53: 67-74.
6. Lieberman JA, Scott Stroup T, Joseph P, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353: 1209-1223
7. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders - DSM-IV-TR. 4th ed, rev. Washington, DC: APA, 2002.
8. Blackwell B. Drug therapy: patient compliance. N Engl J Med 1973; 289: 249.
9. Kozoki Y, Froelicher ES. Lack of awareness and non-adherence in schizophrenia. West J Nurs Res 2003; 25: 57-74.
10. Baldessarini RJ, Tondo L, Faedda GL, et al. Effects of the rate of discontinuing lithium maintenance treatment in bipolar disorders. J Clin Psychiatry 1996; 57: 441-448.
11. Green JH. Frequent rehospitalisation and noncompliance with treatment. Hospital and Community Psychiatry 1988; 39: 963-966.
12. Haywood TW, Kravitz HM, Grossman LS, et al. Predicting the 'revolving door' phenomenon among patients with schizophrenia, schizoaffective, and affective disorders. Am J Psychiatry 1995; 152: 856-861.
13. Weiden PJ, Olfson M. Cost of relapse in schizophrenia. Schizophr Bull 1995; 21: 419-429.
14. Weiden PJ, Kozma C, Grogg A, et al. Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatric Serv 2004; 55: 886-891.
15. Tuninger E, Levander S. Long-term outcome of depot neuroleptic maintenance treatment among chronic psychotic patients. Acta Psychiatric Scand 1997; 96: 347-353.
16. Knapp M, Mangalore R, Simon J. The global costs of schizophrenia. Schizophr Bull 2004; 30: 279-293.
17. Barofsky I, Connolly CE. Problems in providing effective care for the chronic psychiatric patient. In: Barofsky I, Budson BD, eds. The Chronic Psychiatric Patient in the Community: Principles of Treatment. New York: SP Medical and Scientific Books, 1983.
18. Wasylenki DA. The cost of schizophrenia. Can J Psychiatry 1994; 39: S65-69.
19. Dunbar J. Issues in assessment. In: Cohen SJ, ed. New Directions in Patient Compliance. New York: Lexington Books, 1979: 41-57.
20. Evans L, Spelman M. The problem of non-compliance with drug therapy. Drugs 1983; 25: 63-76.
21. Gordis L. Methodological issues in the measurement of patient compliance. In: Sackett DL, Haynes RB, eds. Compliance with Therapeutic Regimens. Baltimore:Johns Hopkins University Press, 1976: 51-69.
22. Mulgirigama LD, Pare CMB, Turner P, et al. Clinical response in depressed patients in relation to plasma levels of tricyclic antidepressants and lyramine pressor response. Postgrad Med J 1977; 53: 155-159.
23. Wilcox DR, Gillan R, Hare EH. Do psychiatric outpatients take their drugs? BMJ 1965; 2: 79.
24. World Health Organization. Adherence to Long-term Therapies, Evidence for Action. Geneva: WHO, 2003: 3-45.
25. Marder SR, Mebane A, Chien CP, et al. A comparison of patients who refuse and consent to neuroleptic treatment. Am J Psychiatry 1983; 140: 470-472.
26. Ruscher SM, de Wit R, Mazmanian D. Psychiatric patients attitudes about medication and factors affecting noncompliance. Psychiatr Serv 1997; 48: 82-85.
27. Blackwell B. From compliance to alliance: a quarter of a century of research. Neth J Med 1996; 48: 140-149.
28. Razali MS, Yahya H. Compliance with treatment in schizophrenia. A drug intervention program in a developing country. Acta Psychiatr Scand 1995; 91: 331-335.
29. Gillis LS, Koch A, Joyi M. Improving compliance in Xhosa psychiatric patients. S Afr Med J 1989; 76: 205-208.
30. Gottesfeld H, Martinez H. The first psychiatric interview: patients who do and do not come. Psychol Rep 1972; 31: 776-778.
31. Bhanji NH, Chouinard G, Margolese HC. A review of compliance, depot intramuscular antipsychotics and the new long-acting injectable atypical antipsychotic risperidone in schizophrenia. European Neuropsychopharmacology 2004; 14: 87-92.
32. Schooler NR. Relapse and rehospitalization: Comparing oral and depot anti-psychotics J Clin Psychiatry 2003; 64: 14-18.
33. Barnes TR, Curson DA. Long-term depot antipsychotics. A risk-benefit assessment. Drug Saf 1994; 10: 464-479.
34. Kane JM. Compliance issues in outpatient treatment. J Clin Psychopharmacol 1985; 5: 22S-27S.
35. Patel MX, Nikolaou V, David AS. Psychiatrists' attitudes to maintenance medication for patients with schizophrenia. Psychol Med 2003; 33: 83-89.
36. Adams CE, Eisenbruch M. Depot fluphenazine for schizophrenia. Cochrane Database of Systematic Reviews 2005; (1): CDOOO307.
37. Pereira S, Pinto R. A survey of the attitude of chronic psychiatric patients living in the community toward their medication. Acta Psychiatr Scand 1997; 95: 464-468.
38. Csernansky JG, Schuchart EK. Relapse and rehospitalisation rates in patients with schizophrenia: effects of second generation antipsychotics. CNS Drugs 2002; 16: 473-484.
39. Joy CB, Adams CE, Lawrie SM. Haloperidol versus placebo for schizophrenia. Cochrane Database Of Systematic Reviews 2001; (2): CD003082.
40. Kane JM. Strategies for improving compliance in treatment of schizophrenia by using a long acting formulation of an antipsychotic: clinical studies. J Clin Psychiatry 2003; 16: 34-40.
41. Allan AT. No shows at a community mental health clinic: a pilot study. Int J Soc Psychiatry 1988; 34: 40-46.
42. Davis MS. Variations in patients' compliance with doctors' advice: An empirical analysis of patterns of communication. Am J Public Health 1968; 58: 274.
43. Owen RR, Fischer EP, Booth BM, et al. Medication noncompliance and substance abuse among patients with schizophrenia. Psychiatr Serv 1996; 47: 853-858.
44. Weiden PJ, Dixon L, Frances A, et al. Neuroleptic noncompliance in schizophrenia. Schizophrenia Research 1991; 1: 285-296.
45. Barnard EJ, Gagiano CA, Joubert G. Patients with chronic mental illness attending outpatient groups - factors influencing compliance. S Afr Med J 1998; 88: 752-758.
46. McEvoy JP, Freter S, Everett G, et al. Insight and the clinical outcome of schizophrenic patients. J Nerv Ment Dis 1989; 177: 48-51.
47. Heinrichs DW, Cohen BP, Carpenter WT. Early insight and the management of schizophrenic decompensation. J Nerv Merit Dis 1985; 173: 133-138.
48. Wright P, Stern J, Phelan M. Core Psychiatry. 2nd ed. Oxford: Elsevier Saunders, 2005: 147-151.
49. Kemp R, Hayward P, Applewhaite G, et al. Compliance therapy in psychotic patients: randomised controlled trial. BMJ 1996; 312: 345-349.
50. Left J, Berkowitz R, Shavit N, et al. A trial of family therapy versus a relatives group for schizophrenia. Br J Psychiatry 1990; 157: 571-577.
51. Weiden PJ, Shaw E, Mann JJ. Causes of neuroleptic noncompliance. Psychiatric Annals 1986; 16: 571-575.
52. Nelson AA, Gold BH, Huchinson RA, et al. Drug default among schizophrenic patients. Am J Psychiatry 1975; 32: 1237-1242.
53. Sadock BJ, Kaplan H, Sadock VA. In: Kaplan and Sadock's Synopsis of Psychiatry: Behavioral Sciences/Clinical Psychiatry. Philadelphia: Lippincott, Williams & Wilkins, 2003: 471-504.
54. Carpenter PJ, Morrow GR, Del gaudio AC, et al. Who keeps the first outpatient appointment? Am J Psychiatry 1981; 138: 102-105.
55. Craig TJ, Huffine CL, Brooks M. Completion of referral to psychiatric services by inner city residents. Arch Gen Psychiatry 1974; 31: 353-357.
56. Rogawaski AS, Edmunson B. Factors affecting the outcome of psychiatric agency referral. Am J Psychiatry 1971; 127: 925-935.
57. Swenson TR, Pekarik G. Interventions for reducing missed initial appointments at a community mental health centre. Community Ment Health J 1988; 24: 205-218.
58. Axelrod S, Wetzler S. Factors associated with better compliance with psychiatric aftercare. Hospital and Community Psychiatry 1989; 40: 397-401.
59. Bond GR, Miller LD, Krumwied RD, et al. Assertive case management in three CMHC's: a controlled study. Hospital and Community Psychiatry 1988; 39: 411-418.
60. Fenton SW, McGlashan TH, Victor BJ, et al. Symptoms, subtype, and suicidality in patients with schizophrenia spectrum disorders. Am J Psychiatry 1997; 154: 199-204.